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Abstract
Background: To compare volumetric-modulated arc therapy (RapidArc) plans with conventional intensity-
modulated radiation therapy (IMRT) plans in anal canal cancers.
Methods: Ten patients with anal canal carcinoma previously treated with IMRT in our institution were selected for
this study. For each patient, three plans were generated with the planning CT scan: one using a fixed beam IMRT,
and two plans using the RapidArc technique: a single (RA1) and a double (RA2) modulated arc therapy. The
treatment plan was designed to deliver in one process with simultaneous integrated boost (SIB) a dose of 59.4 Gy
to the planning target volume (PTV2) based on the gross disease in a 1.8 Gy-daily fraction, 5 days a week. At the
same time, the subclinical disease (PTV1) was planned to receive 49.5 Gy in a 1.5 Gy-daily fraction. Plans were
normalized to 99% of the PTV2 that received 95% of the prescribed dose. Planning objectives were 95% of the
PTV1 will receive 95% of the prescribed dose and no more than 2% of the PTV will receive more than 107%. Dose-
volume histograms (DVH) for the target volume and the organs at risk (bowel tract, bladder, iliac crests, femoral
heads, genitalia/perineum, and healthy tissue) were compared for these different techniques. Monitor units (MU)
and delivery treatment time were also reported.
Results: All plans achieved fulfilled objectives. Both IMRT and RA2 resulted in superior coverage of PTV than RA1
that was slightly inferior for conformity and homogeneity (p < 0.05).
Conformity index (CI95%) for the PTV2 was 1.15 ± 0.15 (RA2), 1.28 ± 0.22 (IMRT), and 1.79 ± 0.5 (RA1). Homogeneity
(D5% -D 95%) for PTV2 was 3.21 ± 1.16 Gy (RA2), 2.98 ± 0.7 Gy (IMRT), and 4.3 ± 1.3 Gy (RA1). RapidArc showed to
be superior to IMRT in terms of organ at risk sparing. For bowel tract, the mean dose was reduced of 4 Gy by RA2
compared to IMRT. Similar trends were observed for bladder, femoral heads, and genitalia. The DVH of iliac crests
and healthy tissue resulted in comparable sparing for the low doses (V10 and V20). Compared to IMRT, mean MUs
for each fraction was significantly reduced with RapidArc (p = 0.0002) and the treatment time was reduced by a
6-fold extent.
Conclusion: For patients suffering from anal canal cancer, RapidArc with 2 arcs was able to deliver equivalent
treatment plan to IMRT in terms of PTV coverage. It provided a better organ at risk sparing and significant
reductions of MU and treatment time per fraction.
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Conventional chemoradiation is the established treat-
ment for anal carcinoma. This organ-preserving
approach gives an equivalent cure than radical surgery
but at the cost of high acute and late pelvic toxicities.
These side-effects can lead to undue treatment breaks
and long overall treatment times and therefore may
negatively influence outcome [1-3].
Intensity-Modulated Radiotherapy (IMRT) is a treat-
ment delivery technique based on inverse planning opti-
misation to modulate intensity beams by using multileaf
collimator (MLC). During radiation delivery, the leaves
are adjusted while the beam is on. IMRT allows the pos-
sibility of producing concave dose distributions and pro-
viding specific sparing of normal tissue [4]. We
performed a dosimetric study about anal canal carci-
n o m aa n ds h o w e dt h a tI M R Tr e s u l t e di ns i g n i f i c a n t
reductions in the doses delivered to the bowel, bladder
and genitalia/perineal skin [5]. These dosimetric findings
were correlated with lower rates of acute GI and GU
morbidities and high conformation to the target volume
for anal carcinoma [6-10].
We started to treat patients suffering for anal carci-
noma with IMRT in May 2007 but we rapidly switch to
volumetric modulated arc therapy (VMAT). Indeed
VMAT is a new form of IMRT optimisation combining
one gantry rotation and the following capabilities: vari-
able dose-rate, variable gantry speed and dynamic MLC
[11]. Details of the RapidArc process and quality assur-
ance are detailed in several publications [11,12]. The
VMAT approach has a number of potential advantages
compared to IMRT: reducing significantly the treatment
time and the number of MU, improving normal tissue
sparing while keeping the adequate coverage.
I nt h ep r e s e n ts t u d yw ec o m p a r e dR a p i d A r cw i t h
IMRT in anal canal patients including iliac crests spar-
ing measurements.
Methods
Patient selection, simulation and treatment planning
Ten patients with localized anal canal carcinoma treated
with IMRT in our institution were selected for this
study. Five patients were staged II, three IIIA, and two
IIIB according to the American Joint Committee on
Cancer 2006 Guidelines (AJCC) [13]. Details are shown
in Table 1.
For all patients, simulation was performed on com-
puted tomography scan (RT 16 PRO CT Simulator,
General Electrics Systems, Cleveland, OH) with a 2.5
mm thick slices from the mid-dorsal spine to the mid-
femur. Patients were simulated in the supine position.
The PTV1 included the subclinical and primary dis-
ease, with inguinal, perirectal, and pelvic area whereas
the PTV2 encompassed the primary disease only. Details
of the delineation of these volumes were recently
described [5].
The considered organs at risk (OAR) were bowel,
bladder, external genitalia/perineal skin (penis and scro-
tum for men and vulva for women), iliac crests, and
femoral heads. For bowel and bladder, a second volume
was created and defined as the considered organ minus
the PTV (bladder - PTV, bowel - PTV) to avoid hot
spots and improve the optimisation. The healthy tissue
was defined as the body covered by the CT scan minus
the PTV.
The treatment plan was designed to deliver in a single
phase process (with simultaneously integrated boost,
SIB) a dose of 59.4 Gy to the PTV2 in 33 fractions (1.8-
G yd a i l yf r a c t i o n s )a n da tt h es a m et i m e4 9 . 5G yt ot h e
PTV1 (1.5-Gy daily fractions).
Considering the radiobiological equivalent dose, 49.5
Gy in 1.5 Gy fractions were considered to be similar to
45 Gy in 1.8 Gy fractions using the linear-quadratic
model and an a/b = 10.
Once the treatment planning was completed, the plan
was normalized to cover 99% of the PTV2 with ≥ 95%
of the prescribed dose. We also checked that 95% of the
PTV1 received 95% of the prescribed dose. No more
than 2% of the PTV was allowed to receive more than
107% of the prescribed dose.
Planning techniques and objectives
Three sets of plans were generated and compared for
this study. All IMRT and RA plans were done using
18MV photons using a Varian clinac with a 120 leaves
Millennium dynamic multileaf collimator (21 EX, Var-
ian, Palo Alto, CA).
IMRT plans
IMRT plans were generated using commercial inverse
planning software (Eclipse, Helios, version 7.2.34,
Varian, Palo Alto, CA). Beam geometry consisted of
seven coplanar fields for the whole pelvis with the
following gantry angles: 0°, 45°, 110°, 180°, 250°, and
315°. Default smoothing values were used during opti-
misation. First optimisation criteria and constraints are
detailed in our recent publication [5]. Dose rate (DR) of
300 MU/min was selected rather than 600 MU/min, in
order to decrease mechanical constraints for multileaves
collimator (MLC), even if dosimetric results are similar.
Calculation was performed with AAA algorithm, and
grid of 2.5 mm.
RapidArc plans
RapidArc optimisation was performed with the version
8.6.05 from Eclipse, (Helios, Varian, Palo Alto, CA). The
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optimisation constraints consisted in the results of
IMRT plans. RapidArc with 1 arc (RA1) corresponded
to a single 360° rotation and RapidArc with 2 arcs
(RA2) to two coplanars arcs of 360° sharing the same
isocenter and optimised independently and simulta-
neously. These two arcs were delivered with opposite
rotation (clock and counter-clock) and so minimize the
off-treatment between the two beams time about 25
seconds.
For RA1, field size and collimator rotation were deter-
mined by the automatic tool from Eclipse to encompass
the PTV. We controlled that the collimator was always
rotated to a value different from zero in order to avoid
tongue and groove effect.
For RA2, the first arc was similar to the one defined
in the RA1 process except for the rotation of the col-
limator, which was 360-X for the second arc (X corre-
sponded to the rotation of the collimator of the
first arc).
To improve the results, we tried to modify constraints
and priority factors on IMRT and RA plans. These para-
meters were modified in function of DVH results for
each patient.
When necessary, field size was minimized to 15 cm in
the X direction. This dimension corresponded of the
maximal displacement of a leave in a MLC Bank. Doing
that, all the leaves positions were possible during the
optimisation process increasing the degree of modula-
tion even if in beam eye view a part of the volume was
excluded of the beam at each gantry position. Globally
rotational delivery permitted to irradiate all the volume
of the PTV during rotation of the Linac.
Evaluation tools
Dose Volume Histograms (DVH) were generated to
evaluate the three different plans.
For PTV, the parameters D2% and D98% were used as
surrogate markers for maximum and minimum doses.
Mean dose (D mean) was also reported.
T h ed e g r e eo fc o n f o r m i t yo ft h ep l a n sw a sd e f i n e da s
the ratio between the volume receiving at least 95% of
the prescribed dose and the volume of the PTV (CI95%).
The homogeneity index (HI) was expressed by D5% -
D95% (difference between the dose covering 5% and
95% of the PTV).
For all patients DVH for OAR (bowel, bladder,
femoral heads, and ilac crests) were calculated and com-
pared. A set of Vx values and D mean was therefore
reported.
For healthy tissue, we detailed the volume of the body
minus PTV receiving low doses (V5, V10, and V20 Gy).
The number of Monitor Units per fraction required
for each plan and the treatment delivery time (from
start to the end of the irradiation) was reported.
Treatment techniques were compared using a Mann
and Whitney test with significant differences at the p <
0.05 level.
Results
PTV volumes, Target coverage, conformity, and dose
homogeneity
The mean PTV1 and PTV2 were 2048 ± 305 cc (range,
1619-2770) and 255 ± 112 cc (range, 122-445), respec-
tively. For the bowel, the mean volume was 461 ± 279
cc (range: 51.6-1011.4). Table 1 shows the different
volumes (PTV, bowel, and bowel-PTV) delineated for
the 10 patients and the results for PTV in terms of cov-
erage and conformity are listed in Table 2.
All the planning objectives were achieved with the
three plans. RA1 reached higher values for the maxi-
mum significant dose (D2%) compared to IMRT (p =
0.004) or RA2 (p = 0.01).
RA2 and IMRT were equivalent for conformity and
homogeneity index with a non significant trend for bet-
ter results with RA2 (p = 0.09). RA1 showed to be
slightly inferior to both IMRT and RA2 for these indices
(p < 0.05). Figure 1 depicts dose distribution for IMRT
and RA2.
Organs at risk
Table 3 details numerical findings.
The bowel DVH parameters (V49.5 V45, V40, V30)
were similar for the three plans. The mean dose was
reduced by 4.7 Gy with RA2 compared to IMRT,
(IMRT: 38.8 ± 12.9 vs 34.1 ± 17.7 Gy, p = NS).
Table 1 Tumor staging, PTV and bowel volumes
Patient 1 2 3 4 5 6 7 8 9 10
AJCC stage II II II II II IIIA IIIA IIIA IIIB IIIB
TNM stage T2N0 T2N0 T2N0 T3N0 T3N0 T2N1 T4N0 T3N1 T2N2 T3N2
PTV1 volume 2187 2010 1933 2010 2082 1775 1935 1916 2770 2160
PTV2 volume 295 203 141 125 445 293 238 122 279 407
Bowel volume 650 587 606 226 385,5 149 51,5 495,5 450 1011
Bowel-PTV volume 265 219 343 188 268 117 36 302 386 662
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volume of bladder irradiated at low and medium doses
was reduced with RA2 compared to IMRT with a trend
towards statistical significance (p = 0.07).
The same trends were observed for skin and genitalia
with a decrease of the irradiated volume to the low and
medium doses (V30: IMRT: 21.7 ± 22.4 Gy vs RA2: 9 ±
15.1 Gy, p = 0.08). The mean dose reduced by 5.6 Gy
(IMRT: 24.5 ± 10.9 vs 18.9 ± 6.9 Gy, p = NS)
Considering the (i) femoral heads and (ii) the iliac crest,(i)
the mean dose was reduced by 3 Gy with a significant sta-
tistical difference (p = 0.03). V45 was inferior to 5% for all
techniques. (ii) No significant difference between the plans
was noted for the parameters V10, V20, and mean dose.
Finally, the planning objectives for healthy tissue con-
sisted in minimize the dose, in particular the low doses
about 5, 10, and 20 Gy. IMRT and RA plans showed
similar results.
Table 2 Dosimetric results for PTV1 (49.5 Gy) and PTV2 (59.4 Gy)
PLANS IMRT RA1 RA2
PTV1 D98%, Gy (%) 47.1 ± 0.8 (95.2) 46.6 ± 1.2 (94.2) 46.3 ± 0.9 (93.7)
D95%, Gy (%) 47.7 ± 0.8 (96.4) 47.8 ± 1.2 (96.6) 47.4 ± 0.8 (95.8)
D2%, Gy (%) 59.8 ± 0.7 (120) 61.6 ± 1.6 (124)
a,b 60.1 ± 1.3 (121)
HI, Gy (D5%-D95%) 11.2 ± 0.6 12.8 ± 1.1
a 15 ± 1.4
CI 1.2 ± 0.1 1.2 ± 0.1 1.17 ± 0.1
Dmean, Gy (%) 52.1 ± 1.5 (105) 53.32 ± 1.7(107) 52.2 ± 1 (105)
PTV2 D98%, Gy (%) 56.8 ± 0.13 (95.6) 57 ± 0.2 (95.9)
a,b 56.8 ± 0.1 (95.6)
D95%, Gy (%) 57.4 ± 0.3 (96.5) 57.8 ± 0.5 (97.4)
a,b 57.4 ± 0.3 (96.5)
D2%, Gy (%) 60.6 ± 0.98 (102) 62.7 ± 1.64 (105)
a,b 60.8 ± 1.3 (102)
HI, Gy (D5%-D95%) 3.0 ± 0.7 4.3 ± 1.3
a,b 3.21 ± 1.16
CI 1.2 ± 0.21 1.8 ± 0.5
a,b 1.15 ± 0.15
Dmean, Gy (%) 58.9 ± 0.4 (99.2) 60.3 ± 1.1 (101.6)
a 59.2 ± 0.9 (99.7)
a if the difference with IMRT is significant.
b if the difference with RA2 is significant for RA1.
PTV: Planning Target Volume, Dx%: Dose received by x% of the volume, HI: Homogeneity Index, CI: Conformity Index, D mean: Dose mean.
Figure 1 Dose distribution by A: Intensity Modulated Radiation Therapy (IMRT) and B: Volumetric Modulated Arc Therapy (VMAT)
RapidArc*.
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3 and 4.
Monitor Units and Delivery time
The IMRT plans required a mean of 1646 ± 332 MUs per
fraction whereas the RA1 plans required 80% less (330 ±
52 MUs, p = 0.0002). The use of two arcs resulted to an
slight increase of the number of MU (493 ± 66) compared
to one arc (p = 0.0003). The difference between RA2 and
IMRT remained significant (p = 0.0013).
Compared to a delivery in 14 min for IMRT, treat-
ment time (defined as the start to the end of the irradia-
tion) with RA was definitely shorter and was 1.1 and 2.3
minutes for one and two arcs, respectively.
Discussion
Recent progresses of new technologies in RT are of
great interest for quality of treatment and avoidance of
toxicities for miscellaneous localizations, in particular
for anal canal cancer.
We initially performed a dosimetric study to compare
standard RT3D with IMRT showing a significant
decrease of the irradiated volume of the OAR, especially
for the bone marrow, while keeping an excellent cover-
age of the PTV [5]. Based on these results we decided
to treat patients suffering from anal canal cancer with
IMRT as a standard with promising results in terms of
acute toxicities [7-10]. RapidArc is a promising techni-
que, providing a coverage of the target volume and
spare of organs at risk at least equivalent to IMRT,
while it could reduce significantly the treatment time
and the number of MU required [14-22].
In the present study, RapidArc proved to be equiva-
lent to IMRT for targeting coverage of anal canal but
showed better organ sparing in terms of mean dose. We
also confirmed that RapidArc with two arcs (RA2)
achieve better results than 1 arc (RA1) for consequent
or complex target volume in terms of conformity and
homogeneity [14,17]. Two arcs allowed superior modu-
lation factor during optimisation due to the independent
Table 3 Dosimetric results for organs at risk
organs plans IMRT RA1 RA2
bowel Dmean (Gy) 30.4 ± 7.8 29.9 ± 8.4 27.8 ± 7.3
V30% (cc) 70 ± 26.5 (343 ± 217) 70 ± 27 (343 ± 268) 61.8 ± 24.8 (314 ± 255)
V40% (cc) 47.7 ± 29.5 (248 ± 182) 49.5 ± 23 (252 ± 203) 42.7 ± 20.8 (224 ± 118)
V45% (cc) 35.3 ± 21 (193 ± 155) 36.4 ± 19.8 (192 ± 159) 31.5 ± 17.7 (171 ± 150)
V49.5% (cc) 9.8 ± 15.8 (63 ± 95) 14.9 ± 15.6 (84 ± 99) 10.4 ± 11 (58 ± 82
bladder Dmean (Gy) 39.1 ± 4.2 38.8 ± 4.2 37.5 ± 5.4
V30% 81.9 ± 15.1 80.4 ± 13.6 70.3 ± 19.4
V40% 46 ± 17.3 45.6 ± 17.2 40.2 ± 17.2
V45% 30.8 ± 17 30.1 ± 16.1 26.9 ± 15.5
genitalia Dmean (Gy) 24.5 ± 10.9 19.4 ± 7.3 18.9 ± 6.9
V20% 62.1 ± 33 51.3 ± 31.6 48 ± 31
V30% 21.7 ± 22.4 11.8 ± 17.3 9 ± 15.1
2.3 ± 6,2 1.7 ± 4.9 1.2 ± 3.6
Iliac crests Dmean (Gy) 20.4 ± 7.2 20.6 ± 5.2 19.6 ± 4.4
V10% 55.3 ± 15.7 60.1 ± 15.9 58.9 ± 18.2
V20% 37.6 ± 9,2 45.25 ± 13.9 40.6 ± 10.5
Femoral heads D mean (Gy) 27.5 ± 2.4 26.2 ± 2.2 24.6 ± 4.1
V45% 2.2 ± 3,3 2.2 ± 2.3 1.7 ± 1.9
Dmean (Gy) 27.2 ± 2.4 26.85 ± 2.9 24.1 ± 3.2
a
V45% 0.8 ± 1 1.7 ± 1.9 1.3 ± 1.5
Healthy tissue V5% 55.7 ± 5.4 57 ± 5.1 57.6 ± 5.1
V10% 47 ± 5 46.7 ± 6 47.2 ± 5.7
V20% 31.9 ± 3.9 33.4 ± 7 28.8 ± 4.8
IMRT: Intensity Modulated Radiation Therapy, Vx%: Volume receiving x% of the prescribed dose, D mean: Dose mean a the difference between RA2 and IMRT is
significant.
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Page 5 of 9Figure 3 Dose-volume histograms for bowel, genitalia, and bladder. RA, Rapidarc; IMRT, intensity-modulated radiotherapy.
Figure 2 Dose-volume histograms for PTV. RA, Rapidarc; IMRT, intensity-modulated radiotherapy
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Page 6 of 9optimisation, and unrelated sequence of MLC shape,
gantry speed and dose rate combinations. Some particu-
lar options have to be considered for better modulation
compared to one arc, particularly the decrease of the
MLC in the X direction allowing the optimization pro-
cess. This approach allows better homogeneity un the
target volume and erases the hot spots outside the PTV
compared to IMRT (Figure 1).
Clivio et al.[14] published also similar results for PTV
but showed different benefit for the OAR, namely for
the bowel tract. In one hand the PTV volumes are
higher in our series (PTV1 minus PTV2 = 1793 ± 283
cc vs 1307 ± 355 cc) due to a 1-cm margin from the
CTV to the PTV (8 mm for Clivio et al.). We also deli-
neated the lymph node CTV as recommended by Taylor
and al. [23] using a margin of 1 cm around the vessels.
In the other hand, we found lower bowel volumes (461
± 279 cc vs. 2483 ± 774 cc). Indeed, Gallagher et al.
estimated that 1/3 of the small intestine volume would
correspond to 660 cc leading to a maximal entire
volume of 2000 cc [24].
Our mean irradiated volume above 30 Gy was about
314 cc with RA2 but 844 cc in the Clivio et al. report
[14]. Regarding correlation between dosimetric para-
meters and acute toxicity, Devisetty et al. [9] showed
higher acute GI toxicity for V30 > 450 cc and ≤ 450 cc
(33% vs. 8%, p = 0.003, respectively).
Regarding acute hematologic toxicity, Mell et al. sug-
gested an association between dosimetric parameters for
iliac crests and acute hematologic toxicities, especially in
the range of low doses (10 and 20 Gy) [25-27]. We did
not find a significant difference between IMRT and RA
for these values shown acceptable when compared with
3D [5]. Other dosimetric parameters were also interest-
ing with constraints for bone marrow given for higher
doses in the RTOG 0529 protocol (V30, V40, and V50)
[28] showing only 23% grade 3-4 leucopenia [10].
Considering late toxicities, we referred to the publica-
tion of Emami et al. [29] asking for a TD 5/5 (probability
of developing 5% of chronic toxicity within 5 years) for
bowel, bladder, and femoral heads. Long-term follow-up
are warranted before drawing definitive conclusions.
One of particular interest of RapidArc is the reduction
of the time to deliver each fraction and the number of
required MU [14,15,18,30]. IMRT plans presented in
this study were wider than 15 cm in the direction of the
Figure 4 Dose-volume histograms for iliac crests and femoral heads. RA, Rapidarc; IMRT, intensity-modulated radiotherapy; FH, femoral
head.
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and doubling the number of fields. Dose rate about 600
MU/min for IMRT would reduce the beam on time, but
not the effective treatment time, which is mainly due to
the multiples beams and the “off-time” necessary to
move from one to another. The number of MU required
is higher due to the sliding window technique. A “step
and shoot” technique might lead to lower values. By
contrast, treatment with RA is performed simulta-
neously with rotation by a dynamic MLC adaptation to
the target structure during the rotation (the open sur-
face is more important than for sliding window) which
reduces the number of MU. For two arcs, the rotation
in clock and counter-clock directions allows minimized
off-time (25 seconds between the 2 arcs). There is no
doubt that the reduced treatment time may impact on
the treatment quality avoiding long and uncomfortable
treatment for the patient and reducing the risk of
internal organ motion during the fraction. In addition,
more time can be spared for on-line control imaging.
A such prolonged fraction delivery time may also have
an impact on treatment outcome, due to the increase
in cell survival by recovery from sub lethal damage
[31,32].
One of the downfalls of IMRT is the potential risk of
second cancer [33-36]. Theoretically, the significant
reduction of MU with RapidArc decreases scattered
dose and may reduce the risk of secondary malignancy.
The impact of irradiation of healthy tissue at low doses
remains unresolved with the use of RapidArc even if
this technique is capable to reduce medium and integral
body doses [15,30].
Conclusion
Compared to IMRT, RapidArc provides an equivalent
coverage of PTV and OAR sparing while reducing the
number of MU and the treatment time delivery. These
improvements have led us to implement rapidly this
technique into the clinic. Nine patients have already
been treated with RapidArc using two arcs.
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